← Leaderboards
Julie D Saba
University Of California, San Francisco
$16,403,080
Attributed
$16,403,080
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,403,080 · 14
By mechanism
R01$11,833,396 · 5
R21$1,591,275 · 4
R61$1,193,262 · 1
S10$955,700 · 2
RC1$825,447 · 1
R13$4,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Sphingolipids”
- Yusuf Awni Hannun · Medical University Of South Carolina$30,274,744
- Timothy Tun Hla · Boston Children'S Hospital$22,231,469
- Sarah Spiegel · Virginia Commonwealth University$19,116,930
- Besim Ogretmen · Medical University Of South Carolina$18,386,608
- Charles E Chalfant · Va Veterans Administration Hospital$12,100,824
- Lina M Obeid · Medical University Of South Carolina$11,320,750
Research focus
SphingolipidsSphingosine 1-PhosphateMetabolismEnzymesCellsSignal TransductionSphingosine-1-Phosphate LyaseLyaseBaseTissuesLipidsFamilyMediatingKnockout MicePreventMouse ModelAffectApoptosisIntestinesPathway InteractionsResponseInflammationCeramidesMalignant Neoplasms
Grant awards (54)
Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis$682,244
R01 · FY2025 · HD · contact PI
Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling$565,250
R61 · FY2025 · HL · contact PI
Characterizing a novel mouse model linking sphingolipid metabolism to multi-organ fibrosis$246,000
R21 · FY2025 · OD · contact PI
Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis$104,973
R01 · FY2025 · HD · contact PI
Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling$62,762
R61 · FY2025 · HL · contact PI
Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis$54,947
R01 · FY2025 · HD · contact PI
Characterizing the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS): a fundamental step in the development of a targeted cure for this novel atypical sphingolipidosis$693,471
R01 · FY2024 · HD · contact PI
Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling$565,250
R61 · FY2024 · HL · contact PI
Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome$463,150
R21 · FY2024 · TR · contact PI
Validating absolute lymphocyte count and plasma sphingosine-1-phosphate as disease biomarkers of sphingosine phosphate lyase insufficiency syndrome in anticipation of a pyridoxine clinical trial$201,875
R21 · FY2023 · TR · contact PI
Validating absolute lymphocyte count and plasma sphingosine-1-phosphate as disease biomarkers of sphingosine phosphate lyase insufficiency syndrome in anticipation of a pyridoxine clinical trial$242,250
R21 · FY2022 · TR · contact PI
Endogenous and Dietary Sphingolipids as Modulators in Inflammatory Bowel Disease$363,375
R01 · FY2021 · DK · contact PI
Endogenous and Dietary Sphingolipids as Modulators in Inflammatory Bowel Disease$395,171
R01 · FY2020 · DK · contact PI
Endogenous and Dietary Sphingolipids as Modulators of Inflammatory Bowel Disease$532,446
R01 · FY2019 · DK · contact PI
Endogenous and Dietary Sphingolipids as Modulators of Inflammatory Bowel Disease$393,750
R01 · FY2018 · DK · contact PI
Endogenous and Dietary Sphingolipids as Modulators of Inflammatory Bowel Disease$109,272
R01 · FY2018 · DK · contact PI
S1P Lyase in colon cancer$70,000
R01 · FY2017 · CA · contact PI
S1P Lyase in colon cancer$314,090
R01 · FY2016 · CA · contact PI
S1P lyase in colon cancer$84,823
R01 · FY2016 · CA · contact PI
S1P Lyase in colon cancer$39,300
R01 · FY2016 · CA · contact PI
S1P Lyase in colon cancer$314,090
R01 · FY2015 · CA · contact PI
Agilent 6490 Triple Quadrupole Mass Spectrometer$523,369
S10 · FY2014 · OD · contact PI
S1P Lyase in colon cancer$304,668
R01 · FY2014 · CA · contact PI
S1P lyase in colon cancer$166,500
R01 · FY2014 · CA · contact PI
IVIS Spectrum small animal imaging system$432,331
S10 · FY2013 · OD · contact PI
Sphingolipid Metabolism in Drosophila Development$322,002
R01 · FY2013 · GM · contact PI
S1P Lyase in colon cancer$314,090
R01 · FY2013 · CA · contact PI
Sphingolipid Metabolism in Drosophila Development$333,680
R01 · FY2012 · GM · contact PI
S1P Lyase in colon cancer$61,560
R01 · FY2012 · CA · contact PI
Sphingolipid Metabolism in Drosophila Development$333,680
R01 · FY2011 · GM · contact PI
S1P Lyase in colon cancer$295,065
R01 · FY2011 · CA · contact PI
FASEB SRC on Lysophospholipd Mediators in Health and Disease$4,000
R13 · FY2011 · CA · contact PI
Sphingolipid Metabolism in Drosophila Development$337,050
R01 · FY2010 · GM · contact PI
S1P Lyase in colon cancer$304,190
R01 · FY2010 · CA · contact PI
Soy sphingadienes and related compounds in colon cancer chemoprevention and treat$198,000
R21 · FY2010 · AT · contact PI
Endogenous sphingosine-1-phosphate as a radioprotector of intestinal tissues$99,950
RC1 · FY2010 · AI · contact PI
Sphingosine Phosphate:Regulation and Role in Cancer$322,582
R01 · FY2009 · CA · contact PI
S1P Lyase in colon cancer$304,190
R01 · FY2009 · CA · contact PI
Soy sphingadienes and related compounds in colon cancer chemoprevention and treat$240,000
R21 · FY2009 · AT · contact PI
Endogenous sphingosine-1-phosphate as a radioprotector of intestinal tissues$233,101
RC1 · FY2009 · AI · contact PI
S1P Lyase in colon cancer$325,190
R01 · FY2008 · CA · contact PI
Sphingosine Phosphate:Regulation and Role in Cancer$322,582
R01 · FY2008 · CA · contact PI
Endogenous sphingosine-1-phosphate as a radioprotector of intestinal tissues$492,396
RC1 · FY2007 · AI · contact PI
Sphingosine Phosphate:Regulation and Role in Cancer$378,232
R01 · FY2007 · CA · contact PI
S1P Lyase in colon cancer$319,440
R01 · FY2007 · CA · contact PI
Sphingosine Phosphate:Regulation and Role in Cancer$385,831
R01 · FY2006 · CA · contact PI
Sphingolipid Metabolism in Drosophila Development$297,042
R01 · FY2006 · GM · contact PI
Sphingosine Phosphate:Regulation and Role in Cancer$340,213
R01 · FY2005 · CA
Sphingolipid Metabolism in Drosophila Development$304,190
R01 · FY2005 · GM
Sphingolipid Metabolism in Drosophila Development$304,190
R01 · FY2004 · GM
Sphingolipid Metabolism in Drosophila Development$303,564
R01 · FY2003 · GM
SPHINGOSINE PHOSPHATE--REGULATION AND POTENTIAL ROLE IN$343,823
R01 · FY2002 · CA
SPHINGOSINE PHOSPHATE--REGULATION AND POTENTIAL ROLE IN$333,807
R01 · FY2001 · CA
SPHINGOSINE--REGULATION AND POTENTIAL ROLE IN CANCER$324,083
R01 · FY2000 · CA